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(VSVind.G) mediates broad tissue tropism and efﬁcient
cellular uptake. Lentiviral vectors (LVs) are particularly prom-
ising, as they can efﬁciently transduce non-dividing cells and
facilitate stable genomic transgene integration; therefore,
LVs have an enormous untapped potential for gene therapy
applications, but the development of humoral and cell-medi-
ated anti-vector responses may restrict their efﬁcacy. We
hypothesized that G proteins from different members of the
vesiculovirus genus might allow the generation of a panel
of serotypically distinct LV pseudotypes with potential for
repeated in vivo administration. We found that mice hyperim-
munized with VSVind.G were not transduced to any signiﬁ-
cant degree following intravenous injection of LVs with
VSVind.G envelopes, consistent with the thesis that multiple
LV administrations would likely be blunted by an adaptive im-
mune response. Excitingly, bioluminescence imaging studies
demonstrated that the VSVind-neutralizing response could
be evaded by LV pseudotyped with Piry and, to a lesser extent,
Cocal virus glycoproteins. Heterologous dosing regimens
using viral vectors and oncolytic viruses with Piry and Cocal
envelopes could represent a novel strategy to achieve repeated
vector-based interventions, unfettered by pre-existing anti-
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Lentiviral vectors are promising gene delivery systems in the treat-
ment of both hereditary and acquired diseases.1 However, in vivo
lentiviral vector (LV) gene therapy is still at a preclinical development
stage,2–5 while ex vivo therapies using hematopoietic stem and pro-
genitor cells and T cells are in clinical use.6–10 One of the major hur-
dles in in vivo LV gene therapy advancement is the immune responses
directed toward LVs, which limit the efﬁcacy and safety of the ther-
apy.1,11 Likewise, the primary immune response elicited following
the administration of vesicular stomatitis virus Indiana strain
(VSVind) has led to the generation of strongly neutralizing anti-
bodies, and it has limited the efﬁcacy of the oncolytic therapy, pre-
cluding repeated administrations.12,13126 Molecular Therapy: Nucleic Acids Vol. 17 September 2019 Crown
This is an open access article under the CC BY-NC-ND license (httpIt has been reported that systemic administration of LVs induces a
primary immune response through CD4+ T cell-mediated mecha-
nisms directed toward the LV envelope and/or core proteins.14,15 In
this case, although the efﬁcacy and safety of the initial vector admin-
istration should not be affected, the effect of subsequent doses of ther-
apymay be limited. Although the development of these antibodies did
not limit transduction efﬁciency, strongly neutralizing antibodies
toward the matrix (p17) and capsid proteins (p24) limited the efﬁcacy
of a subsequent administration of the same vector.14 On the other
hand, the effects of neutralizing anti-envelope antibodies to LV efﬁ-
cacy remain to be fully explored in animal models.16
LV-derived antigens, such as envelope and capsid proteins, are
expected to induce robust immune responses, both in humans and
animal models, following intravenous administration.14 While the
acute effector phase will eventually subside, immunological memory
is likely to be protracted due to development of central memory
T cells, memory B cells, and long-lived plasma cells, thereby rendering
subsequent doses of the same vector less effective.17,18 As LVs may
also activate innate immune responses in parallel to adaptive immune
pathways, their administration may exacerbate any anti-vector im-
mune responses, due to the induction of inﬂammatory pathways.19
Here we have examined the inhibitory effects of pre-existing anti-en-
velope immunity on subsequent LV administrations pseudotyped
with the gold standard vesicular stomatitis virus Indiana strain glyco-
protein (VSVind.G), and we demonstrated that diverse vesiculovirus
G proteins (VesGs), namely that of Cocal virus (COCV), Maraba
virus (MARAV), and Piry virus (PIRYV), may allow LVs to circum-
vent this pre-existing humoral immunity.Copyright ª 2019
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Intravenous LV Injection Prompts a Specific Neutralizing
Anti-envelope Response
(A) Neutralization activity of pooled sera on VSVind.G- and RDpro-pseudotyped LVs
pre- (dotted lines with clear symbols) and post-adsorption (solid lines with filled
symbols) with HEK293T cells. (B) Neutralization activity of pooled sera on VesG-LV
post-adsorption. Data shown represent the mean ± SD of three repeats performed
in duplicates.
www.moleculartherapy.orgRESULTS
Intravenous LV Administration Induces Envelope-Specific
Neutralizing Antibodies
To determine whether intravenous (i.v.) LV administration would
lead to the production of envelope-speciﬁc neutralizing antibodies,
three female BALB/c mice were injected with 5  107 transducing
units (TU)/mouse VSVind.G-pseudotyped LVs (VSVind.G-LV),
and blood samples were collected after 21 days. Sera were isolated
and pooled, and neutralizing activity was determined through an
in vitro LV neutralization assay previously described (Figure 1).20
VSVind.G-LV infection was blocked in a dose-dependent manner;
however, a similar effect was also observed for LVs pseudotyped
with the unrelated feline endogenous retrovirus RD114-derived
(RDpro) envelope (Figure 1A, dotted lines). This unspeciﬁc neutral-
izing activity suggested that the inhibition of LV infection might bedue to antibodies directed against proteins on the vector surface ac-
quired from the producer cells during the LV production, namely,
host-cell proteins. This anti-HEK293T response could be against pro-
teins encoded by the human leukocyte antigen (HLA) complex, as a
similar major histocompatibility complex class I (MHC-I)-directed
immune response has been reported in hemophilia B mouse
models.21
To isolate the anti-VSVind.G response, 150 mL pooled sera was ﬁrst
incubated with 1  107 HEK293T cells on ice for 1 h, and then it
was submitted to neutralization assay analysis. This incubation
successfully removed anti-HEK293T antibodies, as, after adsorption,
the neutralizing activity against RDpro-LV was lost. This then re-
vealed a strongly neutralizing anti-VSVind.G response (Figure 1A,
solid lines), which was speciﬁc to VSVind.G, as LVs pseudotyped
with the other three VesGs remained infectious (Figure 1B).
Pre-existing Anti-envelope Immunity Blocks the Subsequent LV
Administration
A challenge study was then designed to explore the mechanism
behind the observed neutralizing humoral response. However,
because in vivo administration of these LV constructs would elicit
an anti-HEK293T response, thereby confounding interpretation of
infectivity data following any subsequent LV exposure, a different
strategy was used to induce pre-existing immunity: repeated injec-
tion of adjuvanted G protein (Gth) isolated from wild-type
VSVind.22,23 More speciﬁcally, BALB/c mice were bi-laterally
immunized subcutaneously (s.c.) with 4 mg Gth protein mixed
with Sigma Adjuvant System Oil (for a total of 8 mg protein/mouse).
Mice were boosted 2 weeks following the primary immuni-
zation, using the same procedure (Figure 2A). Then 3 weeks later,
one of the immune response groups (immunization + challenge
[IC]) was challenged by i.v. injection of 5  107 TU/mouse
VSVind.G-LV, encoding both ﬁreﬂy luciferase (FLuc) and EGFP
(Figure 2D). Immunization-only (IO) and challenge-only (CO)
groups were either only immunized and received PBS injections
or received a vector dose following immunization and boost with
the adjuvant only. The study was terminated 21 days post-challenge,
at which time terminal bleeds were collected. During the study,
none of the mice showed signs of distress (observation), and no
substantial changes in body weights were measured.
Prior to the LV challenge, the serum antibody levels in immunized
mice were assessed (data not shown), and the induced immune
response was characterized to ensure a VSVind.G-speciﬁc neutral-
izing response was elicited. Characterizations of pre-challenge serum
samples revealed that the induced humoral response was neutralizing
and VSVind.G speciﬁc (Figures 2B and 2C). Analyses revealed that
the antibody response induced via Gth immunization exhibited
similar properties to the one elicited by i.v. administration of LV.
Following VSVind.G-LV challenge, luciferase expression was moni-
tored via bioluminescence imaging for 21 days (Figures 2E and 2F).
At day 2 post-challenge, a strong luciferase signal could be detected
in CO mice, mainly localized at the liver, spleen, and inguinal andMolecular Therapy: Nucleic Acids Vol. 17 September 2019 127
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Figure 2. Pre-existing Anti-VSVind.G Immunity
Hinders the Efficacy of a Subsequent VSVind.G-LV
Injection
(A) Timeline of the study. Immunization and boost points
are identified by light blue arrows, while the black arrow
indicates the time of LV challenge. Red arrows designate
the times at which blood samples were collected through
tail vein bleeds. Green lines show the days on which mice
were imaged. At termination of the study, terminal bleeds
and post-mortem organ harvest were performed. w,
weeks. Neutralization activity of pooled IO sera on (B)
VSVind.G- and RDpro-pseudotyped LVs and (C) other
VesG-LVs. Data shown represent the mean ± SD of three
repeats performed in duplicates. (D) Schematic repre-
sentation of the LV vector construct. (E) Representative
bioluminescence images of transduced and naive mice
at the three time points of days 5, 14, and 21 post-
challenge. Localization and the intensity of the luciferase
signal are depicted in a heatmap. (F) Photon emission
from each mouse was quantified as radiance (p/s/cm2/sr)
post-imaging, using region of interest analysis in Living
Image software. Each dot represents a mouse and the
horizontal bar shows the median. Two-way ANOVA
followed by Bonferroni multiple comparison test was
performed to analyze the significance of luciferase
expression differences in LV-negative, CO, and ICmice at
each imaging time point (indicated on the graph) as well
as overall throughout the study (indicated in the legend).
In all comparisons, the differences between LV-negative
and IC samples were not significant (data not shown).
(****p < 0.0001, **p < 0.01, *p < 0.05). Neg, negative.
Molecular Therapy: Nucleic Acidsauxiliary lymph nodes (Figure 2E). This signal was sustained for
2 weeks. On day 14, clearance of the luciferase signal from the liver
and spleen was observed, however, luciferase expression in the lymph
nodes and the tracheal region remained constant until the termina-
tion of the study. This was conﬁrmed via post-mortem analysis of
the luciferase activity in the organs (data not shown). A similar vector
clearance has been previously reported in the liver.24
In the CO group, overall measured radiance levels throughout
the study were signiﬁcantly higher compared to that of the128 Molecular Therapy: Nucleic Acids Vol. 17 September 2019IC group (p < 0.0001) (Figure 2F). In
addition, a multiple comparison of each im-
aging time point revealed signiﬁcant differ-
ences in luciferase expression in the CO
group compared to the IC group and
naive mice (LV negative) (Figure 2F). In the
IC group, luciferase expression could not be
detected, and the radiance of mice in the IC
group remained comparable to that of LV-
negative mice for the whole study (overall
average radiances 2.01  105 and 1.24 
105 p/s/cm2/steradian [sr], respectively).
Thus, the induced anti-envelope immunity
signiﬁcantly reduced the efﬁcacy of asubsequent viral vector injection utilizing the envelope homolo-
gous to the immunogen.
LV Challenge Acts as a Boost for Pre-existing Anti-envelope
Immunity
The LV challenge of pre-immunized mice may boost the immune sys-
tem, prompting an even stronger response that blocks vector trans-
duction. To investigate this, we explored the neutralizing activity of
the sera isolated from IC mice sacriﬁced on day 21 post-challenge
(IC-D21 mice). As previously described, sera were pooled, adsorbed
A B
C
D
Figure 3. LV Challenge of Pre-immunized Mice
Strengthens the Neutralizing Activity
(A) The strength of VSVind.G-LV neutralization activity
elicited by Gth immunization, LV challenge, and the
combination of both. The calculated IC50 values were as
follows: immunization (IO sera pooled), 6.96  103;
vector challenge (CO sera pooled), 1.20  103; and
immunization + challenge (IC sera pooled), 1.51  104.
(B) Cross-neutralizing activity of sera isolated from IC
terminal bleeds. Solid lines signify the neutralization effect
observed, while the dotted lines indicate the lack of
neutralization. Data shown represent the mean ± SD of
three repeats performed in duplicates. To calculate IC50
values, curves were fitted using the software GraphPad
Prism 5 modeled as an [inhibitor] versus response curve
with variable hill slopes. (C) Isotypes of antibodies pro-
duced following Gth immunization versus VSVind.G-LV
challenge. Wells were coated overnight with 50 ng/well
recombinant VSVind.G, and they were incubated with
pooled serum samples isolated from pre- and terminal
bleeds. The absorbances measured from pre-bleed
serum samples were regarded as background and sub-
tracted from terminal bleed sera. One-way ANOVA with
Tukey’s multiple comparison post-test was performed to
compare absorbance levels within the experimental
groups (****p < 0.0001, **p < 0.01; n.s., not significant).
Data shown represent mean ± SD of one experiment
performed in triplicates. (D) Anti-VesG antibodies induced
by Gth immunization-boost regimen. Sera obtained from
pre-bleed and pre-challenge bleeds (i.e., post-immuni-
zation) were pooled, and the amounts of antibodies
directed against the four VesGs were determined via
LV-based ELISA. The amount of antibodies recognizing
PIRYV.G was significantly less compared to the other
three VesGs. One-way ANOVA followed by Holm-Sidak’s multiple comparison post-test was performed to analyze the significance of the amount of anti-VesG antibodies
produced via Gth immunization (***p < 0.001). Data shown represent mean ± SD from two experiments performed in duplicates.
www.moleculartherapy.orgto HEK293T cells, and incubated with VSVind.G- and VesG-pseudo-
typed LVs (Figure 3). As expected, i.v. LV injection to mice pre-
immunized with Gth strengthened the neutralizing anti-envelope
response, shifting the half maximal inhibitory concentration (IC50)
approximately 50-fold (from 0.007 to 0.0001) (Figure 3A). This
response prompted by the combination of s.c. immunization and
i.v. vector injection was ten times more potent than the one induced
by LV challenge only (IC50 values of 0.0001 and 0.001, respectively).
To understand the difference in strength of antibody response to Gth
immunization in comparison to VSVind.G-LV challenge, an immu-
noglobulin (Ig)-isotyping ELISA was performed on pooled serum
samples (Figure 3C). This revealed that, while protein immunization
induces a potent IgG1 response (p < 0.0001 for IgG1a and p < 0.01 for
IgG1b), the increase in IgG levels following LV challenge was modest
(not statistically signiﬁcant). This indicates that the Gth immuniza-
tion induced a stronger antigen-speciﬁc humoral response. On the
other hand, following VSVind.G-LV administration there was a sig-
niﬁcant (p < 0.01) increase in IgG3 and IgM levels, indicative of acti-
vation of innate immunity and inﬂammatory pathways. Together, the
data imply that, while LV challenge induced a modest anti-G accom-panied with a strong anti-vector immune response, only a strong anti-
protein antigen response was observed following Gth immunization.
Furthermore, to investigate the lack of cross-neutralization observed
by sera acquired from immunized mice, we performed LV-based
ELISAs (Figure 3D). Wells were coated with unenveloped (DEnv)
and VesG-LVs and incubated with pooled serum samples. It revealed
that the levels of antibodies present in the sera that recognized
COCV.G and MARAV.G were similar to that of VSVind.G, which
was signiﬁcantly higher (p < 0.001) than that of PIRYV.G. This high-
lighted that, in a heterologous LV challenge, PIRYV.G-pseudoyped
vectors might outperform both MARAV.G-LV and COCV.G-LV.
In addition, the data demonstrated that, although no cross-neutrali-
zation was observed, cross-reactive antibodies were produced
following Gth immunization.
Interestingly, although LV administration and Gth immunization
alone did not produce any detectable cross-neutralizing antibodies
against VesG (Figures 1B and 2C), sera of IC mice demonstrated
weak neutralizing activity against MARAV.G- and COCV.G-pseudo-
typed LVs (IC50 0.2 for COCV.G and 0.06 for MARAV.G)Molecular Therapy: Nucleic Acids Vol. 17 September 2019 129
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closest phylogenetic relatives of VSVind.G,25 may share several im-
munodominant epitopes, resulting in antibody cross-reactivity and
neutralization.
Neutralizing Anti-envelope Response Can Be Circumvented
Using Other VesGs
The VSVind.G-LV challenge study described above demonstrated
that immunization with Gth elicited a sufﬁciently high-quality and
high-magnitude immune response to prevent VSVind.G-LV-medi-
ated transduction following vector administration i.v.. In fact, the
IC50 of this neutralizing activity was approximately 10-fold higher
(i.e., weaker neutralization) compared to that elicited by i.v. injection
of VSVind.G-LV (Figure 3A). Likely this reﬂects the additional
contribution of antibodies targeting non-G-related epitopes (e.g.,
anti-HEK293T, as described in the previous section). Nonetheless,
these data imply sequential homologous LV-dosing regimens may
well be heavily compromised by the development of anti-vector
antibodies.
We proposed that a heterogeneous panel of envelopes could be uti-
lized to sidestep this response, allowing for sequential injections to
achieve desired levels of therapeutic transgene expression. To test
this theory, four VesGs, VSVind.G, COCV.G, MARAV.G, and
PIRYV.G, were selected. A study with the same Gth immunization-
boost regimen was designed (Figure 4A). However, after priming
the immune system for anti-VSVind.G immunity, mice were chal-
lenged with either VSVind.G-LV or other VesG-LVs. LV gene deliv-
ery efﬁcacy was assessed utilizing bioluminescence imaging, and the
study was terminated 7 days post-challenge.
Like the previous study, no adverse health effects were observed at any
time point, and pre-challenge serum antibody levels were assessed via
LV-based ELISA to ensure the presence of a VSVind.G-speciﬁc
humoral response (data not shown).
Overall a similar biodistribution pattern was observed for all four
pseudotypes (Figure 4B). In non-immunized mice, initial levels of
reporter gene delivery by all pseudotypes were comparable (median
radiances: VSVind.G, 1.23  108 p/s/cm2/sr; COCV.G, 3.67 
107 p/s/cm2/sr; MARAV.G, 3.73  107 p/s/cm2/sr; and PIRYV.G,
5.01  107 p/s/cm2/sr). These levels remained comparable for all
pseudotypes throughout 7 days, indicating that satisfactory gene
delivery can be achieved with all envelopes (Figure 4C).
On the other hand, LV challenges of Gth-immunized mice revealed
intriguing differences regarding VesGs’ capacity to evade the humoral
immune response. Although radiances of IC mice challenged with
COCV.G-LV and MARAV.G-LV were reduced compared to the
CO mice, it was substantially higher than that of VSVind.G-LV
(>100-fold on days 2–5), which was again blocked entirely. The
weak cross-neutralization we observed against COCV.G and
MARAV.G in vitro (Figure 3B) translated into a stronger in vivo
neutralization of the transducing potential of these pseudotypes.130 Molecular Therapy: Nucleic Acids Vol. 17 September 2019MARAV.G-LV’s gene delivery efﬁcacy was transient, as biolumines-
cence levels dropped considerably by day 7. On the other hand,
sustained FLuc expression with COCV.G-LV in the IC group was
achieved at comparable levels to the CO group and approximately
100-fold higher than IC-VSVind.G. Strikingly PIRYV.G-LV efﬁcacy
was unaffected throughout, and signiﬁcantly higher levels of
transgene expression were achieved (p < 0.0001 on days 2 and 5,
p < 0.01 on day 7) (Figure 4D).
These data demonstrated that PIRYV.G-LV outperformed the other
pseudotypes, completely evading the neutralizing anti-VSVind.G
antibody response. While COCV.G-LV transduction was partially
blocked, viable levels of transgene expression were detected and im-
mune evasion could be bolstered with a higher dose.
PIRYV.G-LV Infection Results in Similar Biodistribution Despite
Different Receptor Usage
In the CO group of VesG-LV challenge studies, all four pseudotypes
demonstrated similar tissue distribution based on the biolumines-
cence signals observed (Figure 4B). Furthermore, the level of estab-
lished transgene expression in vivo was within 3-fold for all four
pseudotypes. The four VesGs investigated throughout this work
have varying degrees of sequence homology on the amino acid level
(>40% and >70% for VSVind.G, MARAV.G, and COCV.G) (Fig-
ure S2), and they are phylogenetically and serologically related.
Therefore, we hypothesized that these G proteins may share similar
tissue tropism through their receptor usage.
VSVind.G’s primary receptor has been identiﬁed as the low-density
lipoprotein receptor (LDLR).26,27 To this end, we ﬁrst evaluated the
interaction between soluble recombinant LDLR (sLDLR) and G pro-
teins expressed on the surface of HEK293T cells. As in neutralization
assays, RDpro envelope was utilized as a negative control, since its
primary receptor has been identiﬁed as ASCT-2, a neutral amino
acid transporter.28,29 While COCV.G and MARAV.G bound to
sLDLR (Figure 5A), PIRYV.G, like the unrelated RDpro, did not
interact with the recombinant receptor protein. Recently, Nikolic
and colleagues27 demonstrated that, while VSVind.G has evolved to
interact with cysteine-rich domains of LDLR and other LDLR family
members, another vesiculovirus G protein from Chandipura virus
does not utilize this receptor. Here we demonstrate that while close
phylogenetic relatives of VSVind.G, MARAV.G and COCV.G, share
its receptor usage, the more distant PIRYV.G does not. The phyloge-
netic closeness of PIRYV.G and Chandipura G20 implies that vesicu-
loviruses might be split into at least two groups regarding their
primary receptor for cell entry.
This discrepancy in binding was further explored through an infec-
tion inhibition assay, in which HEK293T cells were challenged with
LVs at two MOIs in the presence and absence of sLDLR. Like the
binding proﬁles, PIRYV.G-LV and RDpro-LV infections were unaf-
fected by the presence of sLDLR in the media (Figure 5B). On the
other hand, other VesG-LV infections were blocked in a dose-
dependent manner, with on average 90% infecton inhibition achieved
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Figure 4. Circumventing Pre-existing Anti-VSVind.G
Immunity by Using Other VesGs
(A) Timeline of the study. Immunization and boost points
are identified by light blue arrows, while the black arrow
indicates the time of LV challenge. Red arrows designate
the times at which blood samples were acquired through
tail vein bleeds. Green lines show the days on which mice
were imaged. At termination of the study, terminal bleeds
and post-mortem organ harvest were performed. w,
weeks. (B) Representative bioluminescence images of
transduced and naive mice at the three time points of
days 2, 5, and 7 post-challenge. Localization and the
intensity of the luciferase signal are depicted in a heat-
map. The envelopes of the challenge vector are indicated
at the top of the images, and the experimental groups are
located at the bottom. The time points when the images
were acquired are indicated on the left. (C) Photon
emission from each mouse was quantified as radiance
(p/s/cm2/sr) post-imaging, using region of interest anal-
ysis in Living Image software. Each data point represents
a mouse and the horizontal bar shows the median.
Different colors indicate the pseudotype of the challenge
vector; solid dots stand for the IC group and crosses
stand for the CO group. (D) Two-way ANOVA followed
by Bonferroni multiple comparison test was performed to
compare relative radiance levels in CO and IC groups.
Comparisons are summarized in a table. Neg, negative;
n.s., not significant.
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Figure 5. PIRYV.G Does Not Interact with sLDLR
(A) VesG- and RDpro-expressing HEK293T cells were incubated with (left) VSV-Poly and anti-RD114 antiserum to determine envelope expression and (right) sLDLR in
parallel. The cells were then probed with the respective secondary antibodies to determine envelope expression and anti-6XHis-tag antibody for sLDLR binding. PIRYV.G did
not bind to sLDLR, while the other VesGs demonstrated similar levels of interaction with the soluble receptor protein (the maximum difference between the calculated mean
fluorescence intensity [MFI] values was <3-fold). Data shown are one of the three repeats performed. Black, mock; purple, VSVind.G; green, COCV.G; orange, MARAV.G;
pink, PIRYV.G; yellow, RDpro. (B) HEK293T cells were challenged with GFP expressing VesG- and RDpro-pseudotyped LVs at MOIs (top) 0.1 and (bottom) 0.5 in the
absence and presence of sLDLR. The infection rates were analyzed 48 h later via flow cytometry, and they were normalized to that of sLDLR-free samples. The percentages
of GFP of sLDLR-free samples were 2%–10% and 13%–30% for MOIs 0.1 and 0.5, respectively. Data shown represent relative infection ± SD from three experiments
performed in duplicates.
Molecular Therapy: Nucleic Acidswith 3 mg/mL sLDLR. The infection hindrance observed, or lack
thereof in the case of PIRYV.G, suggested that, while MARAV.G
and COCV.G share LDLR as their main receptor with VSVind.G,
PIRYV.G does not.VesG Immunogenicity and the Development of Anti-VesG
Immune Response
The investigation of immune response development in response to
VesG-LV challenge provided essential insights on VesG immunoge-
nicity. For this analysis, in vitro neutralization assays were carried out,
and neutralizing activity was determined by normalizing CO and IC
group responses to that of control group (i.e., non-immunized, non-
challenged) (Figure 6).
Pooled sera from CO mice challenged with COCV.G-LV (CO-
COCV.G) and MARAV.G-LV (CO-MARAV.G) demonstrated
neutralizing activities against their respective pseudotypes (Figures
6A and 6B). The IC50 values for both neutralization proﬁles were
comparable, implying similar levels of immunogenicity (Fig-
ure 6G). Interestingly, while the response against COCV.G-LV
was speciﬁc, MARAV.G-LV administration yielded cross-neutral-
izing antibodies against VSVind.G, once again indicating
homology between immunodominant neutralizing epitopes be-
tween these two closely related G proteins. On the other hand,132 Molecular Therapy: Nucleic Acids Vol. 17 September 2019surprisingly, CO-PIRYV.G did not hinder PIRYV.G-LV infectivity
(Figure 6C).
Furthermore, the presence of anti-VSVind.G antibodies at the time of
the LV challenge boosted the homologous neutralizing anti-VesG
response against all pseudotypes (Figure 6D). While IC50 values
of COCV.G and MARAV.G decreased by approximately 2- and
4-fold, respectively, PIRYV.G-LV infection was partially hindered
(<50%). The induction of PIRYV.G-LV-neutralizing response was
conﬁrmed by the level of anti-PIRYV.G antibodies in CO and IC
sera (Figure 6F).
A similar trend was evident for the neutralizing anti-VSVind.G
response. All VesG-LV challenges but PIRYV.G-LV boosted the
pre-existing immunity, resulting in a stronger VSVind.G-LV neutral-
ization (Figure 6E). While VSVind.G challenge had the most potent
effect, enhancing the neutralizing response by approximately
100-fold, both COCV.G andMARAV.G-LV administrations resulted
in the production of cross-neutralizing antibodies and a modest
improvement on pre-existing G immunity.DISCUSSION
In this study, we have explored anti-vector immunity and potential
approaches to circumvent the negative effect of this on viral
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Figure 6. Neutralizing Antibody Response after VesG-LV Administration
Neutralizing activities of (A) CO-COCV.G, (B) CO-MARAV.G, and (C) CO-PIRYV.G sera isolated from terminal bleeds. (D) Neutralizing activity of IC-COCV.G, IC-MARAV.G,
and IC-PIRYV.G sera isolated from terminal bleeds against their respective pseudotypes. (E) Neutralizing activity of IC-VesG sera isolated from terminal bleeds against
VSVind.G-LV compared to the neutralizing activity observed after s.c. Gth immunization. Solid lines signify the neutralization effect observed, while the dotted lines indicate
the lack of neutralization. The calculated IC50 values were as follows: immunization only, 7.15 103; COCV, 5.21  103; MARAV, 2.49  103; PIRYV, 1.90  102; and
VSVind, 1.52 104. Data shown represent the mean ± SD of three repeats performed in duplicates. (F) Anti-PIRYV.G antibodies produced following PIRYV.G-LV challenge
of non-immunized (CO) and pre-immunized (IC) mice. One-way ANOVA followed by Tukey’s multiple comparison post-test was performed to analyze the significance of the
amount of anti-PIRYV.G antibodies produced (****p < 0.0001). Data shown represent mean ± SD from two experiments performed in duplicates. (G) Table summarizing
measured IC50 values of the observed neutralizing activity of CO- and IC-VesG sera. All neutralization experiments were performed as outlined in the Materials and Methods
following sera adsorption to HEK293T cells. To calculate IC50 values, curves were fitted using the software GraphPad Prism 5modeled as an [inhibitor] versus response curve
with variable hill slopes.
www.moleculartherapy.orgvector-based therapeutic paradigms in the context of LVs. We
have demonstrated that i.v. injection of VSVind.G-LVs into naive
mice induces a potent and speciﬁc neutralizing response (Figure 1).
Interestingly, challenging naive mice also revealed a potent anti-
HEK293T response, which blocked infection of LVs pseudotyped
with the unrelated RDpro envelope in vitro. This is thought to
be mainly mediated by antibodies that recognize antigens acquiredby the vectors during production (e.g., MHC-I). This underlined a
major obstacle in studying repeated administration of viral vectors
to non-immune-privileged sites in animal models. In addition, the
generation of such allo-antibodies may lead to cytotoxicity and
allogeneic immune responses in both in vivo and ex vivo gene ther-
apies in patients.17,21 These data underscore the importance of
stringent quality control criteria with respect to host cell proteinMolecular Therapy: Nucleic Acids Vol. 17 September 2019 133
Molecular Therapy: Nucleic Acidslevels in viral vectors destined for clinical development and biolog-
ical therapies in general.
It has been hypothesized that the induction of a primary immune
response, although it wouldn’t affect the initial vector injection, could
be problematic for subsequent administrations.1,16,18 Here we have
demonstrated the potency of a pre-existing anti-envelope immunity.
VSVind.G-LV gene delivery efﬁcacy was signiﬁcantly reduced to the
point of complete abrogation (Figure 2). However, utilizing a phylo-
genetically distant relative of VSVind.G, PIRYV.G, we were able to
demonstrate repeated administration is achievable (Figure 4). In
addition, while the efﬁcacy of MARAV.G-LVs was substantially
reduced, COCV.G-LVs were partially neutralized but achieved sus-
tained transgene delivery, which may be boosted to higher levels
with increased dosage.
The degree of immune evasion achieved by the three different pseu-
dotypes could be explained with regard to phylogenetic relatedness.
MARAV.G and COCV.G are two of the closest relatives of
VSVind.G, with 78% and 72% homology on the amino acid level,
respectively (Figure S2).20 In vitro neutralization assays performed
using the sera isolated from terminal bleeds of IC-VSVind.G dis-
played weak but neutralizing cross-reactivity against these two pseu-
dotypes (Figure 3). This implied that these three closely related G
proteins share immunodominant epitopes, which neutralizing anti-
bodies recognize. Furthermore, they may also share several other
immunogenic determinants, which are recognized by non-neutral-
izing antibodies. These antibodies most probably contribute to
concerted efforts of the immune system through several mecha-
nisms: coating the viral vectors and leading to vector aggregation,
aiding deposition of complement cascade proteins leading to vector
opsonization, and contributing to antigen presentation stimulating
the activation of macrophages and cytotoxic T cells.30–34 This would
explain the more robust viral transduction hindrance observed
in vivo compared to the modest vector neutralization in vitro. On
the other hand, PIRYV.G, with only 40% amino acid homology,
may lack these determinants, rendering the antibodies unable to
bind to the glycoprotein.
In addition, administration of these four different pseudotypes led
to distinct humoral immune responses. Following i.v. injection of
VesG-LV into naive mice, envelope-speciﬁc-neutralizing antibodies
were detected for VSVind.G, COCV.G, and MARAV.G, but not for
PIRYV.G (Figures 6A–6C). PIRYV.G-LV infection was blocked
partially (<50%) only with IC-PIRYV.G sera, while complete
neutralization was observed for both CO- and IC-VesG sera for
other pseudotypes. Similarly, the administration of VSVind.G-,
COCV.G-, and MARAV.G-LVs to pre-immunized mice strength-
ened the pre-existing anti-VSVind.G immunity, while PIRYV.G-
LV injection had no effect (Figure 6E). It can be deduced from the
data that PIRYV.G, in comparison to the other three G proteins,
may be less immunogenic and might need several more boosts
and/or sequential administrations to elicit a robust neutralizing
response.134 Molecular Therapy: Nucleic Acids Vol. 17 September 2019A recent study in which the low pH conformation of another vesicu-
lovirus, Chandipura virus (CHAV), was investigated revealed several
evolutionary variances among VesGs.35 Comparison of the CHAV.G
3D structure and previously elucidated VSVind.G structures high-
lighted selective pressure of primary immune responses, with regard
to themain antigenic sites of the G proteins.22,23 Therefore, the overall
structural differences between PIRYV.G (a closer phylogenetic rela-
tive of CHAV.G in comparison to VSVind.G) and the other tested
VesGs could lead to substantially different antigen presentation.
Therefore, the way antigenic domains are structured may dictate
the immunogenicity difference as well as the lack of cross-neutraliza-
tion observed with pooled mice sera. Another reason behind the lack
of neutralizing PIRYV.G-LV antibodies may be the number of glyco-
protein spikes acquired by LVs during assembly and budding from
the producer cells. PIRYV.G-LVs may have a considerably smaller
number of glycoproteins compared to the other VesG-LVs, therefore
providing the immune system with fewer immunogenic targets and
leading to a weaker response.
Transgene delivery levels in the CO group mice, in both studies, pro-
vided insights on in vivo effectiveness of complement-mediated viral
vector inactivation. Serum sensitivity of wild-type (WT) VSVind and
VSVind.G-LV is well established in the literature.30,36–40 We have pre-
viously reported that COCV.G, MARAV.G, and PIRYV.G are substan-
tially more resistant to complement-mediated inactivation by both
human and mouse sera.25 Recent studies have demonstrated the
dose-dependent nature of complement-mediated LV inactivation.3,21,41
It has been suggested that the titers utilized in vivo are high enough to
saturate this neutralizing response. In vivo bioluminescence imaging
(Figure 4B) and luciferase activity detected in organs (data not shown)
harvested post-mortem have conﬁrmed this. VSVind.G-LV transduc-
tion efﬁciency was comparable to that achieved with serum-resistant
pseudotypes. This highlights that in vivo transduction efﬁciency may
have not been hindered substantially by the complement system in
this experimental setting. Furthermore, while a similar overall bio-
distribution was observed for all four pseudotypes (Figure 4B; post-
mortem organ bioluminescence data not shown), a closer investigation
revealed that they do not utilize the same receptor as their major
cellular entryway (Figure 5). Thismay alter the types of cells transduced
within a tissue, and, therefore, it may affect any further anti-transgene
immune responses and, hence, long-term transgene expression levels.
In the past, translation from animal models to clinical settings for gene
therapy has not always been straightforward. However, taken together,
this study serves as the proof of principle for a vector administration
method in gene therapy, and it has some implication also for oncolytic
virotherapy. Recombinant versions of the VSV backbone have shown
signiﬁcant potential for cancer immunotherapy.42,43 Human infec-
tions with VSVind are very rare and isolated to regions where VSVind
is endemic. Seroprevalance in the human population is, therefore,
likely to be low, with the general population largely free of pre-existing
neutralizing antibodies.44 Thus, we speculate the pseudotyping ap-
proaches outlined in this report could be applied to allow repeated in-
jections over more protracted time frames. Furthermore, it is possible
www.moleculartherapy.orgthat VSV pseudotyped with these unconventional G proteins may
have improved tumor targeting, speciﬁcity, and replicative capacity;
but, this is purely speculative at this stage. However, we do believe
this method will allow tailoring a panel of pseudotypes for every indi-
vidual, as well as improved potential for repeated systemic administra-
tion of vectors and viruses to achieve sustained therapeutic levels of
transgene expression and anti-tumor effects.
MATERIALS AND METHODS
Cell Culture
In all experiments, HEK293T cells were used. The cell line was main-
tained in DMEM (Sigma-Aldrich, St. Louis, MO, USA), supple-
mented with 10% heat-inactivated fetal calf serum (Gibco, Carlsbad,
CA, USA), 2 mM L-Glutamine (Gibco), 100 U/mL penicillin (Gibco),
and 100 mg/mL streptomycin (Gibco). Cells were kept in cell culture
incubators at 37C and 5% CO2.
LV Preparation
Three-plasmid co-transfection into HEK293T cells was used to make
pseudotyped LV, as described previously.45 Brieﬂy, 2 107 cells were
seeded in 15-cm plates. Then 24 h later, they were transfected using
FuGene6 (Promega, Madison, WI, USA) with the following plasmids:
3.75 mg pCCL.Fluc.2A.EGFP (ﬁreﬂy luciferase and EGFP-expressing
vector plasmid),46 2.5 mg p8.91 (Gag-Pol and Rev expression
plasmid),45 and 2.5 mg VesG expression plasmids previously
described.20,25 Then 4 h after transfection, medium was changed to
OptiMEM (Gibco), supplemented with 2 mM L-Glutamine (Gibco),
100 U/mL penicillin (Gibco), and 100 mg/mL streptomycin (Gibco).
Vector-containing media were collected 48 and 72 h after transfec-
tion, pooled, passed through Whatman Puradisc 0.45-mm cellulose
acetate ﬁlters (SLS, UK), and concentrated100-fold by ultra-centri-
fugation at 22,000 rpm (87,119  g) for 2 h at 4C in Beckmann
Optima LK-90 ultracentrifuge using the SW-28 swinging bucket
rotor. Titers of vectors were estimated on HEK293T cells via ﬂow
cytometry and qPCR measuring proviral copies, as previously
described.20,25 For all concentrated VesG-pseudotyped vectors, titers
ranged from 0.6 to 1.1  109 TU/mL (Figure S1).
Mice
All animal studies described were done according to protocols
approved by Biological Services Division (BSD) at the National Insti-
tute for Biological Standards and Control (NIBSC) and within the
remit of a Home Ofﬁce Project License (PPL 70/8091). Animals
were purchased from Charles River Laboratories (Kent, UK). The
6- to 8-week-old female BALB/c mice with a minimum weight of
18 g were used for both experiments. Mice were immunized and
boosted with wild-type VSVind.G protein produced by thermoly-
sin-limited proteolysis of viral particles (Gth),22,23 subcutaneously
using the Sigma Adjuvant System (Sigma-Aldrich) at 0.08 mg/mL
antigen concentration. LVs were administered i.v. into the tail vein.
Blood sampling was performed by tail vein bleeding. Serum was ob-
tained by centrifuging clotted blood samples at 10,000 g for 15 min
at 4C. Serum was stored at 20C until further use.In Vivo Bioluminescence Imaging
Transduction efﬁcacy, transgene expression, and biodistribution of
the viral vectors were monitored using the IVIS Spectrum In Vivo
Imaging System (PerkinElmer, Waltham, MA, USA). Mice were in-
jected intraperitoneally with D-Luciferin (PerkinElmer) in PBS at a
150 mg/kg body weight dose prior to subjection to general anesthesia
via isoﬂurane inhalation in the induction chamber. Mice were then
transferred to the imaging chamber while anesthesia was maintained,
and images were captured between 10 and 15 min post D-Luciferin
injection. Mice were monitored during recovery after imaging.
Images were analyzed, and radiance was determined via region of in-
terest (ROI) analysis using Living Image software (PerkinElmer).Serum Neutralization Assay
To determine the presence of neutralizing antibodies in murine sera
and the strength of the neutralizing immune response induced, an
infection assay was performed. Brieﬂy, HEK293T cells were seeded
in a 96-well plate at a density of 2  104 cells/well with 200 mL me-
dium containing 8 mg/mL polybrene. For all neutralization experi-
ments except for the one shown in Figure 1, pooled serum samples
were ﬁrst adsorbed to HEK293T cells: prior to incubating with LVs,
sera were pooled and incubated with 1  107 HEK293T cells/
150 mL sera on ice for 1 h. Following, adsorbed sera were serially
diluted in plain OptiMEM to 12 different concentrations ranging
from 1:2 dilution to 1:6,250,000 dilution. Of each serum dilution,
10 mL was mixed 1:1 v/v with the indicated LV pseudotypes at
4.0  105 TU/mL titer, incubated at 37C for 1 h, and plated on
the cells. At 48 h after challenging the cells with the serum-LV mixes,
cells were trypsinized and analyzed for GFP expression by ﬂow
cytometry. Measured titers were normalized to that obtained after
mixing the LVs with dilutions of sera collected from control mice
(i.e., non-immunized and non-challenged), using the following
equation:
Infection % =
Titer of LV incubated with experimental sera
Titer of LV incubated with control sera
100:
The data obtained from the above analysis were plotted against anti-
serum dilutions using the graphing and statistics software GraphPad
Prism 5. Furthermore, non-linear regression analysis was carried out
using the same software to ﬁt neutralization ([inhibitor] versus
response) curves and calculate IC50 values (Figure S3).Infection Assay to Evaluate the Role of LDLR in Lentiviral Entry
To determine whether the human LDLR plays a role in mediating
infection of pseudotyped LVs, an infection assay was performed in
the presence and absence of sLDLR. HEK293T cells were seeded at
a density of 2  104 cells/well in 96-well plates in 100 mL complete
medium. Then 3 h later, these cells were incubated, for 30 min at
37C, with four different concentrations of sLDLR (0.05, 0.5, 1.5,
and 3 mg/mL) (R&D Systems, Minneapolis, MN, USA). The cells
were then challenged with GFP encoding VesG- or RDpro-pseudo-
typed LVs at two MOIs (0.1 or 0.5) in a total volume of 120 mL.Molecular Therapy: Nucleic Acids Vol. 17 September 2019 135
Molecular Therapy: Nucleic AcidsThen 48 h later, transduced cells were analyzed for GFP expression by
ﬂow cytometry.
sLDLR Binding to G Protein-Expressing Cells
Cells were transfected with VesG and RDpro expression plasmids20,25
by lipofection using FuGENE6 (Promega, Madison, WI, USA). Cells
were plated in U-bottom 96-well plates at equal densities. Cells
were then incubated with the extracellular polyclonal VSV-Poly20
or anti-RD114 antiserum (NCI, Rockville, MD, USA) at 1:200 or
1:500 dilution, respectively, or 3 mg/mL sLDLR in 1% BSA in PBS
in a total reaction volume of 100 mL. After washing twice with PBS,
cells stained with anti-VSVind.G and anti-RDpro antibodies were
incubated with their respective secondary antibodies. On the other
hand, the cells incubated with sLDLR were stained with an anti-
6XHis-tag antibody, ab18184 (Abcam, UK), against the C-terminal
6XHis-tag on sLDLR to probe for sLDLR binding. Cells were then
washed twice with PBS, ﬁxed in 2% paraformaldehyde (PFA) in
PBS, and analyzed via ﬂow cytometry.
LV-Based ELISA
An ELISA was used to detect anti-VesG antibodies in murine sera.
For this, LVs pseudotyped with different VesGs and with no envelope
(DEnv) were produced as previously described. Total protein concen-
trations of the LV preparations were determined using a Pierce BCA
Protein Assay Kit, according to the manufacturer’s instructions, using
BSA as the standard. A coating mix of 25 mg/mL total protein in PBS
was prepared, and each well of Nunc Maxisorp ELISA plate (Thermo
Fisher Scientiﬁc, UK) was coated at a volume of 100 mL/well overnight
at 4C. The plate was washed three times with 200 mL PBS before
the samples were incubated with 200 mL/well blocking buffer and
2% ﬁsh gelatine (Sigma-Aldrich) in PBS, for 1 h at 37C. The plate
was washed three times with 300 mL/well washing buffer, PBS-
0.05% (v/v) Tween20, before 100 mL/well serum samples diluted in
diluent buffer, 10% fetal calf serum (FCS) (heat inactivated) in PBS,
were added to the wells and incubated at 37C for 2 h. After another
three washes, the samples were incubated with the secondary anti-
body, horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(Jackson ImmunoResearch Laboratories) diluted 1:1,000 in diluent
buffer for 1 h at 37C. Following three washes, 100 mL/well Ultra
TMB-ELISA Substrate (Thermo Fisher Scientiﬁc) was added to
each well incubated at room temperature for 10 min, and the reaction
was stopped by adding an isovolume of 1 M sulfuric acid. The absor-
bance was determined at 450 nm using a FluoStar Omega Plate
Reader (BMG Labtech).
Ig-Isotyping ELISA
Ig-Isotyping Mouse Uncoated ELISA kit (Thermo Scientiﬁc) was
used to perform the analysis. Wells in a Nunc Maxisorp 96-well plate
(Thermo Scientiﬁc) were coated overnight at 4C with 50 ng/well in
PBS recombinant VSVind.G protein (Source Bioscience). Following
blocking, pooled serum samples were added at 1:100 in the diluent
buffer provided and incubated for 1 h at room temperature. Following
incubation for 1 h with rat anti-mouse Ig antibodies provided and
diluted 1:100 in diluent buffer, HRP-conjugated anti-rat IgG (Jackson136 Molecular Therapy: Nucleic Acids Vol. 17 September 2019ImmunoResearch Laboratories) was used to determine the antibody
signal. Absorbance was read using a FluoStar Omega Plate Reader
(BMG Labtech).
Statistical Analyses
All statistical analyses were performed using the GraphPad Prism 5
software (GraphPad, La Jolla, CA, USA). Details of all tests, including
the calculated p values, are indicated in the respective ﬁgure legends.
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